A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs LMB 100 (Primary) ; SEL-403 (Primary) ; Sirolimus (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- 13 Mar 2018 Planned number of patients changed from 40 to 20.
- 12 Mar 2018 According to a Selecta Biosciences media release, first patient has been dosed in this trial.
- 03 Mar 2018 Planned initiation date changed from 8 Mar 2018 to 9 Mar 2018.